NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Ariad Names President and CEO
Paris Panayiotopoulos has been appointed president and CEO of Ariad, an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. Most recently, Mr. Panayiotopoulos was president of EMD Serono. He succeeds Harvey J. Berger, M.D., Ariad’s founder, chairman, and CEO.
At EMD Serono and its parent company Merck KGaA, he achieved organizational turnarounds in the United States, Japan, and Western Europe by building high-performing and trusting teams, and creating an enduring vision and strategy in each role that he served.
Chase Pharmaceuticals Appoints Former Allergan President as CEO
Chase Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders, including Alzheimer’s disease, has named Douglas Ingram CEO. Mr. Ingram replaces John Siebert, who will continue as a senior advisor to the company.
Mr. Ingram brings almost 20 years of biotech, pharmaceutical and medical device leadership to Chase. Most recently, and until its acquisition by Actavis, he was president of Allergan, a global pharmaceutical company.
Dr. Jonathan Yingling
Bind Therapeutics Appoints Chief Scientific Officer
Bind Therapeutics, a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins, has named Jonathan Yingling, Ph.D., to the position of chief scientific officer. In this role, Dr. Yingling is responsible for leading the company’s research and development efforts to identify and pursue new product opportunities to provide meaningful improvements in patient care.
Dr. Yingling joins Bind from Bristol-Myers Squibb, where he was VP, oncology discovery and translational research. During his tenure at BMS, he was responsible for the oncology research portfolio, as well as translational capabilities in oncology and immunoscience, contributing to the discovery and development of potentially transformative medicines in immuno-oncology.
Biothera Pharmaceutical Names CEO
Biothera Pharmaceutical, which is developing a novel cancer immunotherapy that triggers a robust, coordinated immune response against a wide range of cancers, has appointed Barry Labinger as CEO.
Mr. Labinger has experience in oncology drug development involving innate immune modulation, commercialization, and public market funding. Most recently, he served as executive VP and president, biosciences division, at Emergent BioSolutions, where he was responsible for all aspects of product development, manufacturing, and commercialization.
Merz North America Appoints VP, Managed Markets
Merz North America (U.S. affiliate of the global Merz Pharma Group) has appointed Philippe Adams VP, managed markets. In this role, Mr. Adams is primarily responsible for developing Merz’s North American market access and reimbursement strategy to enhance patient access to Merz prescription products.
Before joining Merz, Mr. Adams held the position of VP, managed markets, at Valeant Pharmaceuticals, leading the U.S. payer market access and reimbursement strategies across all business units, including neurology, dermatology, ophthalmology, and gastroenterology.
Digitas Health LifeBrands Adds Veteran Strategists
Rob Avery joins Digitas Health LifeBrands as VP, group director, mobile strategy, building out the agency’s team delivering connected health innovation and mobile apps in the health and wellness space.
He brings more than 18 years of experience, most recently he was VP of product management at PointRoll, where he was responsible for the company’s mobile strategy, product offerings, and partner integrations for product lines across CPG, automotive, and retail clients.
Communications and branding industry veteran Annie Heckenberger brings 20 years of experience to the social strategy department at Digitas Health LifeBrands.
As VP, group director, brand communications strategy, Ms. Heckenberger is charged with leading and developing social media and content through earned and paid strategies, as well as driving social creative and design ways to help ideas travel further wherever they impact behavior.
Ms. Heckenberger brings a unique perspective to social strategy having established Red Tettemer O’Connell + Partners social practice in 2008. As the VP, Earned Media, she led the social and PR practices for the agency and implemented creative brand campaigns.
Advanced Clinical Hires Senior VP
Advanced Clinical, a full-service global CRO, functional outsourcing, and strategic talent acquisition provider, has augmented its staff with the addition of Denise Kurowski, senior VP, FSP, to its leadership team.
Ms. Kurowski brings more than 28 years of leadership and program management experience to Advanced Clinical, and is responsible for the continued growth of the functional services business.
Before joining Advanced, she was executive VP for Strategic Staffing Solutions (S3), an international IT staffing and solutions company. (PV)